MARKET

ENDP

ENDP

Endo Intl
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.55
-0.25
-4.23%
After Hours: 5.56 +0.02 +0.27% 17:46 10/26 EDT
OPEN
5.83
PREV CLOSE
5.79
HIGH
5.84
LOW
5.34
VOLUME
3.60M
TURNOVER
--
52 WEEK HIGH
7.10
52 WEEK LOW
2.080
MARKET CAP
1.27B
P/E (TTM)
-15.8203
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why Endo (ENDP) is Poised to Beat Earnings Estimates Again
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 3d ago
Envarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan
MONTREAL, Oct. 22, 2020 /CNW/ -- Paladin Labs Inc.
CNW Group · 4d ago
Envarsus PA Once-Daily Immunosuppressive Therapy For Kidney And Liver Transplant Patients Is Now Reimbursed In Ontario, Quebec, Manitoba And Saskatchewan
MONTREAL, Oct. 22, 2020 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), announced today that Ontario, Quebec, Manitoba and Saskatchewan now
Benzinga · 4d ago
Endo International Licensing Partner Nevakar Announces FDA Approval For Ephedrine Sulfate Injection As Ready-to-Use Vials
BRIDGEWATER, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food
Benzinga · 4d ago
Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
BRIDGEWATER, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation. Under an exclusive licensing agreement with Endo International’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, Par Pharmaceuticals’ Sterile Products division will launch and distribute the product. This is the first approval under the previously announced collaboration between Nevakar and Endo for the development of five differentiated, sterile injectable products in the U.S. and Canada. Under the terms of the agreement, Nevakar has responsibility to develop and obtain FDA approval for these products and Par Pharmaceuticals’ Sterile Products division will launch and distribute the products.“We are pleased to have received approval for this convenient, patent pending, ready-to-use form of a frequently used treatment for clinically important hypotension during anesthesia. We value our strong partnership with Endo, a respected pharmaceutical company with a significant and growing presence in sterile and critical care products as we pursue our mission to develop innovative pharmaceutical products that improve patient care and quality of life,” stated Navneet Puri, Ph.D., Founder, Chairman and Chief Executive Officer of Nevakar.About Nevakar Inc. Nevakar Inc. is growing as a fully integrated biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Founded in 2015, and headquartered in Bridgewater New Jersey, the Company is focused on developing and commercializing innovative products to address unmet medical needs, thereby improving patient care and quality of life. Nevakar utilizes the 505(b)(2) regulatory pathway, along with its proven expertise in the development of novel and proprietary sterile pharmaceutical products to identify, develop, and obtain regulatory approval for its products. Additional information is available at www.nevakar.com.Investor Contacts:Marshall Woodworth Chief Financial Officer (908) 625-3547 E: mwoodworth@nevakar.comLisa M. Wilson (212) 452-2793 E: lwilson@insitecony.com
GlobeNewswire · 4d ago
OxyContin maker Purdue Pharma to plead guilty to three criminal charges
Privately held Purdue Pharma, the corporate poster child in the opioid epidemic due to its aggressive promotion of pain pill OxyContin, has agreed to plead guilty to three criminal charges
Seekingalpha · 5d ago
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
Zacks · 6d ago
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)
Benzinga · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENDP. Analyze the recent business situations of Endo Intl through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENDP stock price target is 5.34 with a high estimate of 9.00 and a low estimate of 2.750.
EPS
Institutional Holdings
Institutions: 289
Institutional Holdings: 196.62M
% Owned: 85.55%
Shares Outstanding: 229.82M
TypeInstitutionsShares
Increased
67
12.39M
New
52
-3.95M
Decreased
57
13.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.71%
Pharmaceuticals & Medical Research
-1.00%
Key Executives
Chairman/Director
Paul Campanelli
President/Chief Executive Officer/Director
Blaise Coleman
Chief Operating Officer/Executive Vice President
Terrance Coughlin
Executive Vice President
Patrick Barry
Executive Vice President
Domenico Ciarico
Executive Vice President
Domenic Ciarico
Executive Vice President
Rahul Garella
Executive Vice President
Matthew Maletta
Senior Vice President/Chief Accounting Officer/Controller
Jack Boyle
Independent Director
Mark Barberio
Independent Director
Shane Cooke
Independent Director
Nancy Hutson
Independent Director
Michael Hyatt
Independent Director
Roger Kimmel
Independent Director
William Montague
Independent Director
M. Christine Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ENDP
Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Endo International PLC stock information, including NASDAQ:ENDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENDP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENDP stock methods without spending real money on the virtual paper trading platform.